The autoimmune reactivity to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis is potentially pathogenic: Effect of copolymer 1 on MOG-induced disease

1996 ◽  
Vol 243 (S1) ◽  
pp. S14-S22 ◽  
Author(s):  
Avraham Ben-Nun ◽  
Itzhack Mendel ◽  
Ronit Bakimer ◽  
Masha Fridkis-Hareli ◽  
Dvora Teitelbaum ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Myelin Oligodendrocyte Glycoprotein ◽  
Pathogenic Effect ◽  
Copolymer 1 ◽  
Autoimmune Reactivity

Myelin Oligodendrocyte Glycoprotein and Multiple Sclerosis

2018 ◽  
Vol 14 (2) ◽  
Author(s):  
Maria-Eleni Androutsou ◽  
Anthi Tapeinou ◽  
Alexios Vlamis-Gardikas ◽  
Theodore Tselios
Keyword(s):  
Multiple Sclerosis ◽  
Myelin Oligodendrocyte Glycoprotein

Recurrent ataxia and dysarthria in myelin oligodendrocyte glycoprotein antibody-associated disorder

2021 ◽  
Vol 14 (11) ◽  
pp. e245341
Author(s):  
Uddalak Chakraborty ◽  
Shrestha Ghosh ◽  
Amlan Kusum Datta ◽  
Atanu Chandra
Keyword(s):  
Multiple Sclerosis ◽  
Central Nervous System ◽  
Nervous System ◽  
Male Patient ◽  
Myelin Oligodendrocyte Glycoprotein ◽  
Aquaporin 4 ◽  
Clinical Presentations ◽  
Neurological Presentation ◽  
New Biomarkers ◽  
Demyelinating Disorders

The spectrum of central nervous system demyelinating disorders is vast and heterogeneous and, often, with overlapping clinical presentations. Misdiagnosis might occur in some cases with serious therapeutic repercussions. However, introduction of several new biomarkers such as aquaporin-4 IgG and myelin oligodendrocyte glycoprotein IgG has made distinction between diseases such as multiple sclerosis and myelin oligodendrocyte glycoprotein antibody-associated disorder easier. Here, we report a case of a 15-year-old male patient with subacute multifocal neurological presentation without encephalopathy, eventually diagnosed as myelin oligodendrocyte glycoprotein antibody-associated disorder.

HLA-DRB1*1501 and response to copolymer-1 therapy in relapsing-remitting multiple sclerosis

Neurology ◽  
2001 ◽  
Vol 57 (11) ◽  
pp. 1976-1979 ◽  
Author(s):  
C. Fusco ◽  
V. Andreone ◽  
G. Coppola ◽  
V. Luongo ◽  
F. Guerini ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Relapsing Remitting ◽  
Copolymer 1 ◽  
Remitting Multiple Sclerosis ◽  
Relapsing Remitting Multiple Sclerosis

Anti-myelin antibodies do not allow earlier diagnosis of multiple sclerosis

2005 ◽  
Vol 11 (4) ◽  
pp. 492-494 ◽  
Author(s):  
E T Lim ◽  
T Berger ◽  
M Reindl ◽  
C M Dalton ◽  
K Fernando ◽  
...  
Keyword(s):  
Magnetic Resonance Imaging ◽  
Multiple Sclerosis ◽  
Magnetic Resonance ◽  
Optic Neuritis ◽  
Myelin Basic Protein ◽  
Basic Protein ◽  
Myelin Oligodendrocyte Glycoprotein ◽  
Clinically Isolated Syndrome ◽  
Resonance Imaging

This study investigates whether the presence of serum and plasma anti-myelin oligodendrocyte glycoprotein (MOG) and anti-myelin basic protein (MBP) in patients presenting with a clinically isolated syndrome compatible with demyelination (CIS) predicts early conversion to multiple sclerosis (MS). Forty-seven patients with CIS (46 with optic neuritis) had anti-MOG and anti-MBP antibodies analysed at baseline, and clinical and magnetic resonance imaging assessments. There was no evidence that the MS status based on either the McDonald or Poser criteria relates to the antibody status.

Myelin basic protein and myelin oligodendrocyte glycoprotein T-cell repertoire in childhood and juvenile multiple sclerosis

2006 ◽  
Vol 12 (4) ◽  
pp. 412-420 ◽  
Author(s):  
Jorge Correale ◽  
Silvia N Tenembaum
Keyword(s):  
Multiple Sclerosis ◽  
T Cell ◽  
Myelin Basic Protein ◽  
Basic Protein ◽  
Myelin Oligodendrocyte Glycoprotein ◽  
T Cell Repertoire ◽  
Adult Onset ◽  
Cell Repertoire ◽  
Juvenile Onset ◽  
Exon 2

Multiple sclerosis (MS) is usually a disease of young adulthood, its clinical onset occurring between 20 and 40 years of age; however, today there is general consensus that MS can also occur in children, adolescents and even in infants. In order to gain further insight into the T-cell repertoire present in this particular group of patients myelin basic protein (MBP)-, MBP exon-2- and myelin oligodendrocyte glycoprotein (MOG)Igd-specific T-cell lines (TCLs) were isolated from 18 patients whose symptoms had started before the age of 16. Epitope specificity was established by measuring proliferative responses, and interferon-g (IFN-g) secretion by using a panel of overlapping synthetic peptides. For MOGIgd, the T-cell response was focused on three main immunodominant epitopes comprising residues 1-26, 36-60 and 63-87. For MBP the predominant immune responses were directed against peptides 83-102, 139-153 and 146-162. When compared to those observed in adult-onset MS patients, anti-MOGIgd specificity and anti-MBP responses showed similar results. Moreover, the number of MBP exon-2 TCLs isolated, and the magnitude of the specific IFN-g secretion induced were similar, both in childhood/juvenile-onset and adult-onset MS patients. Thus, despite differences in the clinical and neuroimaging manifestations of MS, these results would seem to indicate that both the spectrum of MBP found, as well as the MOGIgd epitopes recognized by peripheral blood T cells in MS, appear to be similar for childhood/juvenile-onset and adult-onset patients.

Development of Copolymer 1 (Copaxone®) as a Specific Drug Against Multiple Sclerosis

1999 ◽  
pp. 191-196 ◽  
Author(s):  
Dvora Teitelbaum ◽  
Rina Aharoni ◽  
Masha Fridkis-Hareli ◽  
Ruth Arnon ◽  
Michael Sela
Keyword(s):  
Multiple Sclerosis ◽  
Specific Drug ◽  
Copolymer 1
Sign in / Sign up

Export Citation Format

Share Document